ロード中...
Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
The epidermal growth factor receptor (EGFR) is frequently dysregulated in human malignancies and a validated target for cancer therapy. Two monoclonal anti-EGFR antibodies (cetuximab and panitumumab) are approved for clinical use. However, the percentage of patients responding to treatment is low an...
保存先:
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Landes Bioscience
2011
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3242845/ https://ncbi.nlm.nih.gov/pubmed/22123060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.3.6.17955 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|